Conversely, the emulation of glucose deprivation through the use of glutaminase (GLS) inhibitors increases the susceptibility of intrahepatic cholangiocarcinoma to chemotherapy, indicating the potential for metabolic modulation as an adjunct to conventional anticancer regimens[16]. Here, GLS is linked to cholangiocarcinoma.